AKTS
Strong SellSinkerAktis Oncology, Inc. · Healthcare · United States · $875M cap · $7.2M/day traded
$15.73 +0.0% · close 26 Oct · scored 27 Oct
StockRank up 2.1 since 24 Oct: Momentum up 4.
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
As of 27 Oct 2026, MoatMap's StockRank for Aktis Oncology, Inc. (AKTS) is 12/100, ranked against 24,000+ stocks in 35 markets (Quality 25, Value 29, Momentum 33, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT AKTIS ONCOLOGY, INC.
Read
Aktis Oncology, Inc. is a biotechnology company developing novel radiopharmaceutical therapeutics for the treatment of solid tumors. It focuses on creating targeted alpha-emitting radiopharmaceuticals with improved tumor penetration and systemic distribution, aiming for superior efficacy in oncology. The company is a clinical-stage biotech innovator in the emerging radiopharmaceutical space, seeking to revolutionize cancer treatment through precision medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.5M | 6.5M | 336.9% | 10.1M | 10.6M | 10.3M | 26.1% |
| EPS | -0.51 | -0.82 | -1.26 | -1.21 | — | -1.70 | -1.68 | -2.14 | — |
| Shares | 52.5M | 52.5M | 52.5M | 52.5M | 0.0% | 53.7M | — | — | — |
| Debt | 1.8M | 13.4M | 12.0M | 11.5M | 86.7% | 11.2M | — | — | — |
| Equity | -19.2M | -46.3M | -87.8M | -146.1M | — | — | — | — | — |
| Op CF | -18.1M | -30.0M | 14.8M | -64.1M | — | -75.3M | — | — | — |
| Inv CF | -2.3M | -68.8M | -190.4M | 66.0M | — | — | — | — | — |
| Fin CF | 120.0M | 0 | 183.3M | -1.2M | — | — | — | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKTS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AKTS | Aktis Oncology, Inc.(you) | $875M | 12 | Strong Sell |
| KURA | Kura Oncology, Inc. | $855M | 13 | Strong Sell |
| JBIO | Jade Biosciences, Inc. | $928M | 13 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $925M | 11 | Strong Sell |
| 950260.KQ | Ingenia Therapeutics Inc. | $808M | 11 | Strong Sell |
| AVBP | ArriVent BioPharma, Inc. | $1.0B | 13 | Strong Sell |
| ODTX | Odyssey Therapeutics, Inc. | $942M | 9 | Strong Sell |
| ARDX | Ardelyx, Inc. | $795M | 15 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $886M | 8 | Strong Sell |
| SVRA | Savara Inc. | $867M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.